AbbVie (NYSE:ABBV) has entered into a collaboration agreement with Neomorph for the development of novel molecular glue degraders for multiple targets across oncology and immunology. Under the ...

Big pharma’s interest in using protein degradation as a therapeutic strategy shows no sign of abating, as Novo Nordisk signs a wide-ranging deal with US biotech Neomorph that could be worth up ...

too much grandiose philosophising (something Covenant also suffers from, but gets away with better) and not enough Alien. This time around, Sir Ridley has fixed that, with plenty of neomorph ...